Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Intervalo de año de publicación
1.
J Fr Ophtalmol ; 46(10): 1204-1211, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37658033

RESUMEN

OBJECTIVE: To analyze the long-term results of treatment of active age-related macular degeneration (AMD) with anti-vascular endothelial growth factor (VEGF) agents using the treat-extend-stop (TES) approach, defining predictive factors for stoppage of the treatment and recurrences in a real-world setting. METHODS: Data from 191 eyes treated with intravitreal injections for choroidal neovascularization due to AMD were retrospectively reviewed. Changes in best-corrected visual acuity (BCVA) and membrane activity (optical coherence tomography) were recorded and evaluated over a 48-month follow-up. Logistic regression analysis was used to determine predictors of treatment stoppage and recurrences after stoppage. RESULTS: BCVA improvement was found in 70.5% of eyes at 48 months, and remaining signs of activity in 27.9%. Disease inactivity was achieved in 69 eyes (31.9%), with a relapse of the membrane in 29 of these eyes (42.0%). Significant independent predictors of treatment stoppage were found: no foveal membrane, inactive membrane at 12, 24, 36 and 48 months, extension interval>8 weeks at 12 and 24 months,>15 injections at 24 months, and baseline BCVA>61 letters. Concerning recurrent membranes, only the presence of membrane activity at 36 months and baseline BCVA>61 letters were independent predictors. CONCLUSIONS: Anti-VEGF treatment of AMD using the TES protocol allows for successful visual restoration in most patients, with more likely disease inactivity in those eyes with better baseline BCVA, maintaining signs of membrane inactivity during the first two years of follow-up and requiring fewer injections.


Asunto(s)
Neovascularización Coroidal , Degeneración Macular , Humanos , Inhibidores de la Angiogénesis , Estudios de Seguimiento , Resultado del Tratamiento , Estudios Retrospectivos , Neovascularización Coroidal/diagnóstico , Neovascularización Coroidal/tratamiento farmacológico , Degeneración Macular/diagnóstico , Inyecciones Intravítreas , Fondo de Ojo , Tomografía de Coherencia Óptica
2.
Arch Soc Esp Oftalmol ; 87(3): 82-5, 2012 Mar.
Artículo en Español | MEDLINE | ID: mdl-22423657

RESUMEN

CASE REPORT: We present a case report of a 28-year-old patient with a lesion that is compatible both clinically and histopathologically with conjunctival keratoacanthoma. The treatment given was complete excision and 0.04% mitomycin C eye drops in the postoperative period. The outcome was a complete clinical remission during the follow-up period (6 months). DISCUSSION: It is important to make a correct differential diagnosis between keratoacanthoma and squamous cell carcinoma, as well as carrying out close monitoring after surgery due to the possibility of relapse and conversion to squamous cell carcinoma. For this reason, we propose the use of conjunctival impression cytology as a non-invasive method for monitoring such patients.


Asunto(s)
Enfermedades de la Conjuntiva/diagnóstico , Células Epiteliales/patología , Técnicas de Preparación Histocitológica , Queratoacantoma/diagnóstico , Adulto , Carcinoma de Células Escamosas/diagnóstico , Terapia Combinada , Enfermedades de la Conjuntiva/complicaciones , Enfermedades de la Conjuntiva/tratamiento farmacológico , Enfermedades de la Conjuntiva/patología , Enfermedades de la Conjuntiva/cirugía , Neoplasias de la Conjuntiva/diagnóstico , Diagnóstico Diferencial , Fluorometolona/uso terapéutico , Humanos , Hiperemia/etiología , Queratoacantoma/complicaciones , Queratoacantoma/tratamiento farmacológico , Queratoacantoma/patología , Queratoacantoma/cirugía , Masculino , Mitomicina/uso terapéutico , Pinguécula/etiología
3.
Arch. Soc. Esp. Oftalmol ; 87(3): 82-85, mar. 2012. ilus
Artículo en Español | IBECS | ID: ibc-101340

RESUMEN

Caso clínico: Se presenta el caso de un paciente de 28 años con una lesión compatible clínica e histopatológicamente con queratoacantoma conjuntival. Fue tratado mediante excisión completa, y colirio de mitomicina C al 0,04% en el posoperatorio. El resultado ha sido la remisión clínica completa durante el tiempo de seguimiento (6 meses). Discusión: Es importante hacer un correcto diagnóstico diferencial entre queratoacantoma y carcinoma de células escamosas, así como un estrecho seguimiento postoperatorio por la posibilidad de recidiva o conversión a carcinoma de células escamosas. Para ello proponemos la citología de impresión conjuntival como un método no invasivo para el seguimiento de estos pacientes(AU)


Case report: We present a case report of a 28-year-old patient with a lesion that is compatible both clinically and histopathologically with conjunctival keratoacanthoma. The treatment given was complete excision and 0.04% mitomycin C eye drops in the postoperative period. The outcome was a complete clinical remission during the follow-up period (6 months). Discussion: It is important to make a correct differential diagnosis between keratoacanthoma and squamous cell carcinoma, as well as carrying out close monitoring after surgery due to the possibility of relapse and conversion to squamous cell carcinoma. For this reason, we propose the use of conjunctival impression cytology as a non-invasive method for monitoring such patients(AU)


Asunto(s)
Humanos , Queratoacantoma , Queratoacantoma/complicaciones , Queratoacantoma/diagnóstico , Queratoacantoma/fisiopatología , Queratoacantoma/cirugía , Enfermedades de la Conjuntiva/patología , Enfermedades de la Conjuntiva/cirugía , Neoplasias de la Conjuntiva/diagnóstico , Neoplasias de la Conjuntiva/patología , Enfermedades de la Conjuntiva/diagnóstico , Queratoacantoma/etiología , Queratoacantoma/microbiología , Queratoacantoma/patología , Conjuntiva/cirugía , Enfermedades de la Conjuntiva/complicaciones , Neoplasias de la Conjuntiva/clasificación , Neoplasias de la Conjuntiva/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...